“The Limbal Stem Cells Deficiency market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Limbal Stem Cells Deficiency pipeline products will significantly revolutionize the Limbal Stem Cells Deficiency market dynamics”

The Limbal Stem Cells Deficiency market report provides current treatment practices, Limbal Stem Cells Deficiency emerging drugs, market share of individual therapies, and current and forecasted 7MM Limbal Stem Cells Deficiency market size from 2019 to 2032. The report also covers current Limbal Stem Cells Deficiency treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

 

Key Takeaways from the Limbal Stem Cells Deficiency Market Research Report

• The increase in Limbal Stem Cells Deficiency market size is a direct consequence of increasing prevalent population and launch of emerging therapies in the 7MM.
• According to several secondary sources, Limbal Stem Cells Deficiency (LSCD) is slightly more common in males than in females.
• The leading companies working in the Limbal Stem Cells Deficiency market include Holostem, Kala Pharmaceuticals, RHEACELL GmbH & Co. KG, FGK Clinical Research GmbH, Granzer Regulatory Consulting & Services, Holostem Terapie Avanzate S.R.L, CliPS Co., Ltd, and others.
• Promising Limbal Stem Cells Deficiency Pipeline Therapies in the various stages of development include LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation, Holoclar, KPI-012, and others.
• On April 2022, Holostem Terapie Avanzate S.R.L announced a study of Phase 4 Clinical Trials for Biopsy from donor eye and ECG procedure. The purpose of this trial is to confirm the efficacy of Holoclar at one year after the first treatment in patients suffering from moderate to severe LSCD (Limbal Stem Cell Deficiency) secondary to ocular burns.
• On October 2022, RHEACELL GmbH & Co. KG announced a study of Phase 1 & 2 Clinical trials for LSC2. The aim of this clinical trial is to investigate the efficacy (by monitoring neovascularization and epithelial defects) of up to four doses of the investigational medicinal product (IMP) LSC2 topically administered on the target eye of patients with LSCD. Further, safety of the IMP during and after application will be investigated (by monitoring adverse events [AEs]).

 

Discover more about therapies set to grab major Limbal Stem Cells Deficiency Market Share @ Limbal Stem Cells Deficiency Market Size

 

Limbal Stem Cells Deficiency Overview

Limbal stem cell deficiency (LSCD) is characterized by a loss or deficiency of the stem cells in the limbus that are vital for re-population of the corneal epithelium and to the barrier function of the limbus. When these stem cells are lost, the corneal epithelium is unable to repair and renew itself.

 

Limbal Stem Cells Deficiency Epidemiology Segmentation in the 7MM

• Total Limbal Stem Cells Deficiency Prevalent cases
• Limbal Stem Cells Deficiency Etiology-specific Cases
• Limbal Stem Cells Deficiency Gender-specific Cases
• Limbal Stem Cells Deficiency Type – specific Prevalent Cases
• Limbal Stem Cells Deficiency Diagnosed and Treatable Population

 

Download the report to understand which factors are driving Limbal Stem Cells Deficiency Epidemiology Trends @ Limbal Stem Cells Deficiency Epidemiological Insights

 

Limbal Stem Cells Deficiency Therapeutics Market

Limbal Stem Cells Deficiency Therapeutic options depend on the etiology, severity of symptoms, extent (partial vs. total), and laterality (uni- vs. bilateral) of the disease. Treatment of mild and moderate cases aims at the control of symptoms. In these cases, recovery requires the presence of at least certain numbers of remaining Limbal Stem Cells Deficiency that can restore the corneal epithelium.

 

Limbal Stem Cells Deficiency Market Size

The Limbal Stem Cells Deficiency market size in 7MM was USD 2,672 million in 2022, which is further expected to increase by 2032 at a significant compound annual growth rate (CAGR) for the study period (2019–2032).

 

To know more about Limbal Stem Cells Deficiency Treatment options, visit @ Limbal Stem Cells Deficiency Drugs

 

Limbal Stem Cells Deficiency Emerging Therapy Assessment

The Limbal Stem Cells Deficiency emerging pipeline is very vacant. There are few potential Limbal Stem Cells Deficiency emerging therapies upcoming, the major key players include CliPS (LSCD101) in Phase I, and Kala Pharmaceuticals (KPI-012) which is in preclinical developmental trial.

 

Limbal Stem Cells Deficiency Market Insights

The current Limbal Stem Cells Deficiency pipeline consists of very few drugs, such as KPI-012, developed by Kala Pharmaceuticals. So there is a wide opportunities available to overcome the unmet need so that the market for Limbal Stem Cells Deficiency can increase. Ongoing awareness and research may increase the market.

 

Learn more about the Limbal Stem Cells Deficiency Pipeline Therapies in clinical trials @ Limbal Stem Cells Deficiency Market Landscape

 

Scope of the Limbal Stem Cells Deficiency Market Report

• Coverage- 7MM
• Study Period- 2019-2032
• Limbal Stem Cells Deficiency Companies- Holostem, Kala Pharmaceuticals (NYSE: KALA), RHEACELL GmbH & Co. KG, FGK Clinical Research GmbH, Granzer Regulatory Consulting & Services, Holostem Terapie Avanzate S.R.L, CliPS Co., Ltd, and others.
• Limbal Stem Cells Deficiency Pipeline Therapies- LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation, Holoclar, KPI-012, and others.
• Limbal Stem Cells Deficiency Market Dynamics: Abdominal Aortic Aneurysm Market Drivers and Barriers
• Limbal Stem Cells Deficiency Market Access and Reimbursement, Unmet Needs, Future Perspectives

 

Discover more about Limbal Stem Cells Deficiency Drugs in development @ Limbal Stem Cells Deficiency Ongoing Clinical Trials Analysis

 

Table of Content

1. Key Insights
2. Limbal Stem Cells Deficiency Executive Summary
3. Limbal Stem Cells Deficiency Competitive Intelligence Analysis
4. Limbal Stem Cells Deficiency Market Overview at a Glance
5. Limbal Stem Cells Deficiency Market Disease Background and Overview
6. Limbal Stem Cells Deficiency Patient Journey
7. Limbal Stem Cells Deficiency Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Limbal Stem Cells Deficiency Unmet Needs
10. Key Endpoints of Limbal Stem Cells Deficiency Treatment
11. Limbal Stem Cells Deficiency Marketed Products
12. Limbal Stem Cells Deficiency Emerging Therapies
13. Limbal Stem Cells Deficiency: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Limbal Stem Cells Deficiency Market Outlook
16. Limbal Stem Cells Deficiency Market Access and Reimbursement Overview of
17. Limbal Stem Cells Deficiency KOL Views
18. Limbal Stem Cells Deficiency Market Drivers
19. Limbal Stem Cells Deficiency Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting